Metabolon Verus Kit Commercial Launch
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Sep 08, 2026
The commercial launch of the Metabolon Verus kit expands Metabolon's addressable market from centralized services to in-house laboratory workflows, potentially increasing revenue and market share in the metabolomics tools segment. The positive validation results may enhance Metabolon's reputation and attract new customers, though the company is privately held and not directly publicly traded.
Metabolon announced on September 8, 2026 that its Metabolon Verus Metabolomics Profiling Kit is now available to order in North American markets, marking the company's first decentralized product and its transition from early access to full commercial availability. The kit, first announced in May 2026 at the ASMS Conference, enables laboratories to run standardized metabolomics workflows in-house, integrating sample preparation, quality control, automated compound annotation, and access to Metabolon's Integrated Bioinformatics Platform. Metabolon validated the kit through an early access program involving 10 laboratories across five countries and a ring trial across eight independent laboratories worldwide. The ring trial demonstrated high reproducibility, with an average of 735 metabolites detected per plasma sample set, 89% metabolite overlap between labs, and a median correlation of 0.91 with an accurate truth dataset. The kit is designed to accelerate multiomics research by enabling results in five days and integrating with other omics data. International availability is expected in early 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard